Immune Checkpoint Inhibitors Market
Description
Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
Market Dynamics
The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market. For instance, according to the American Cancer Society, in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.)
Key features of the study
This report provides an in-depth analysis of the global immune checkpoint inhibitors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global immune checkpoint inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune checkpoint inhibitors market
Market Segmentation
By Drug Class
Market Dynamics
The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market. For instance, according to the American Cancer Society, in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.)
Key features of the study
This report provides an in-depth analysis of the global immune checkpoint inhibitors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global immune checkpoint inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune checkpoint inhibitors market
Market Segmentation
By Drug Class
- Programmed Death Receptor-1 (PD-1) Inhibitors
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Cemiplimab (Libtayo)
- Others
- Programmed Death-Ligand 1 (PD-L1) Inhibitors
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
- CTL-4 Checkpoint Inhibitor
- Ipilimumab (Yervoy)
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Lymphocyte-Activation Gene 3 Inhibitors
- Lung Cancer
- Head & Neck Cancer
- Skin Cancer
- Melanoma
- Merkel Cell Carcinoma
- Blood Cancer
- Lymphoma
- Bladder Cancer
- Urothelial Carcinoma
- Renal/Kidney Cancer
- Colorectal Cancer
- Breast Cancer
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Hoffmann-La Roche AG
- AstraZeneca Plc.
- Novartis International AG
- ImmunOs Therapeutics AG
- Immutep Ltd.
- NewLink Genetics Corporation
- Ono Pharmaceutical Co., Ltd.
- Pfizer, Inc.
Table of Contents
151 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Cancer Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Epidemiology
- Collaborations & Partnerships
- Major FDA Approvals & Product Launch Scenario
- Pipeline Analysis
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Porter’s Five Forces Analysis
- 4. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2026 – 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 – 2033
- Segment Trends
- Programmed Death Receptor-1 (PD-1) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Pembrolizumab (Keytruda)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Nivolumab (Opdivo)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Cemiplimab (Libtayo)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Programmed Death-Ligand 1 (PD-L1) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Atezolizumab (Tecentriq)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Avelumab (Bavencio)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Durvalumab (Imfinzi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- CTL-4 Checkpoint Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Ipilimumab (Yervoy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Lymphocyte-Activation Gene 3 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- 5. Global Immune Checkpoint Inhibitors Market, By Cancer Type, 2026 – 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 – 2033
- Segment Trends
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Head & Neck Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Skin Cancer (Melanoma and Merkel Cell Carcinoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Blood Cancer (Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Bladder Cancer (Urothelial Carcinoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Renal/Kidney Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- 6. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2026 – 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 – 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
- 7. Global Immune Checkpoint Inhibitors Market, By Region, 2026 – 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026–2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 – 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
- 8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche AG
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ImmunOs Therapeutics AG
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Immutep Ltd.
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NewLink Genetics Corporation
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ono Pharmaceutical Co., Ltd.
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Introduction
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 9. Section
- References
- Research Methodology
- About Us and Sales Contact
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
